Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.33 |
| ▸ | CALCA | P06881 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.30 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15699563 | 0.82 | MAP3K11 (0.42) | MAP3K11BACE1AKR1B1CALCAFGFR1 | |
| SCHEMBL15117493 | 0.79 | MAP3K11 (0.41) | MAP3K11BACE1CALCAPGRIP6K1 | |
| SCHEMBL15117477 | 0.78 | MAP3K11 (0.40) | MAP3K11BACE1CALCAIP6K1 | |
| SCHEMBL13748469 | 0.75 | BACE1 (0.36) | MAP3K11BACE1CALCAOPRM1 | |
| SCHEMBL31349540 | 0.74 | OPRL1 (0.43) | OPRM1 | |
| SCHEMBL15204715 | 0.74 | AKR1B1 (0.36) | MAP3K11AKR1B1 | |
| SCHEMBL1950989 | 0.72 | CYP1A2 (0.53) | BACE1AKR1B1NR3C2PGR | |
| SCHEMBL550356 | 0.72 | CALCA (0.50) | BACE1CALCAOPRM1CALCRL | |
| SCHEMBL19349361 | 0.71 | MAP3K11 (0.46) | MAP3K11AKR1B1PGRFGFR1 | |
| Hydrochloric Acid SCHEMBL1436147 | 0.71 | CALCA (0.49) | BACE1CALCAOPRM1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |